ADTX logo

ADITXT INC

ADTXNASDAQ
🏆 #5225 by market capUS Equity
$0.01▼ $0.01 (−77.15%)
Live
🔔
Track ADTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 77.2%
7d▲ 0.0%
14d▲ 0.0%
30d▲ 0.0%
ytd▼ 100.0%
1y▼ 100.0%
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
-74.1%
Declining
📊Gross Margin
19.9%
Thin
💵FCF Margin
—
⚖️P/S Ratio
285.3x
Expensive
Otter Score
80
Good

Trading Snapshot

Day Range
$0.01 – $0.01
52-Week Range
$0.00 – $26,360.64
Volume
$2.47B
Avg Volume
$2.31B
Shares Outstanding
998.0M
Next Earnings
Nov 30, 2026

Fundamentals Snapshot

Annual Revenue
$3,195
Last Q Revenue
$12,159
P/E Ratio
—
P/S Ratio
285.3x
EPS (TTM)
$-205,055.95
Dividend Yield
—
Dilution (1yr)
−28.0%

Why Investors Own ADTX

  • ✓High-growth profile — revenue up +41.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 35% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ADTX logo

ADITXT INC

ADTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3K▼ −97.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
8.4%▼ −102.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$20M▼ −29.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$25.7B▲ +153234.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37K▼ −28.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$192K▲ +$6M YoY
StockOtter · stockotter.space

About ADITXT INC

Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it at the forefront of immunology and the broader healthcare landscape.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Ratings

ⓘ
Consensus
Buy
8 analysts
Strong Buy2
Buy4
Hold2
Sell0
Strong Sell0
Ratings as of Jul 2024

Latest News & Updates

🚀
CNBC·2h ago

ADITXT INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift ADTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ADITXT INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.